CBSET taps CRO CILcare to advance preclinical services

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/liza5450)
(Image: iStock/liza5450)

Related tags: Contract research organization, Good laboratory practice

CBSET is expanding its preclinical research service offerings via a partnership with the contract research organization (CRO) CILcare.

CILcare specializes in drug development targeting otic and hearing disorders.

Lexington, MA-based CBSET Inc. is a non-profit good laboratory practice (GLP) translational research institute. 

Through the partnership, the firms will help customers prepare IND packages for drugs intended to target hearing and otic indications. Additionally, the companies will support safety clinical trials that include ototoxicity and auditory function loss as key parameters.

CBSET is the ideal partner in preparing, presenting, and defending GLP studies for regulatory review. The complementarity of the two companies, one expert of the hearing field and the other experienced in GLP-compliant preclinical research, is obvious​,” Celia Belline, CEO, CILcare, commented in the press release.

The companies are launching the new auditory assessment services week at the Preclinical World Congress in Boston.

CBSET also announced the expansion of its preclinical cell therapy offerings. The new service will also be launched next week at the ISSCR 2017 Annual Meeting.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

Related suppliers

Follow us

Products

View more

Webinars